CLDX Relative Valuation
CLDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLDX is overvalued; if below, it's undervalued.
Historical Valuation
Celldex Therapeutics Inc (CLDX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -13.36. The fair price of Celldex Therapeutics Inc (CLDX) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 29.60 USD , Celldex Therapeutics Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：29.60
Fair
Undervalued
-6.72
PE
1Y
3Y
5Y
Trailing
Forward
-4.74
EV/EBITDA
Celldex Therapeutics Inc. (CLDX) has a current EV/EBITDA of -4.74. The 5-year average EV/EBITDA is -2.33. The thresholds are as follows: Strongly Undervalued below -9.65, Undervalued between -9.65 and -5.99, Fairly Valued between 1.32 and -5.99, Overvalued between 1.32 and 4.98, and Strongly Overvalued above 4.98. The current Forward EV/EBITDA of -4.74 falls within the Historic Trend Line -Fairly Valued range.
-4.14
EV/EBIT
Celldex Therapeutics Inc. (CLDX) has a current EV/EBIT of -4.14. The 5-year average EV/EBIT is -9.78. The thresholds are as follows: Strongly Undervalued below -21.81, Undervalued between -21.81 and -15.80, Fairly Valued between -3.77 and -15.80, Overvalued between -3.77 and 2.25, and Strongly Overvalued above 2.25. The current Forward EV/EBIT of -4.14 falls within the Historic Trend Line -Fairly Valued range.
514.92
PS
Celldex Therapeutics Inc. (CLDX) has a current PS of 514.92. The 5-year average PS is 568.50. The thresholds are as follows: Strongly Undervalued below 9.94, Undervalued between 9.94 and 289.22, Fairly Valued between 847.78 and 289.22, Overvalued between 847.78 and 1127.06, and Strongly Overvalued above 1127.06. The current Forward PS of 514.92 falls within the Historic Trend Line -Fairly Valued range.
-7.05
P/OCF
Celldex Therapeutics Inc. (CLDX) has a current P/OCF of -7.05. The 5-year average P/OCF is -11.63. The thresholds are as follows: Strongly Undervalued below -31.01, Undervalued between -31.01 and -21.32, Fairly Valued between -1.94 and -21.32, Overvalued between -1.94 and 7.75, and Strongly Overvalued above 7.75. The current Forward P/OCF of -7.05 falls within the Historic Trend Line -Fairly Valued range.
-8.02
P/FCF
Celldex Therapeutics Inc. (CLDX) has a current P/FCF of -8.02. The 5-year average P/FCF is -14.62. The thresholds are as follows: Strongly Undervalued below -30.42, Undervalued between -30.42 and -22.52, Fairly Valued between -6.72 and -22.52, Overvalued between -6.72 and 1.18, and Strongly Overvalued above 1.18. The current Forward P/FCF of -8.02 falls within the Historic Trend Line -Fairly Valued range.
Celldex Therapeutics Inc (CLDX) has a current Price-to-Book (P/B) ratio of 3.29. Compared to its 3-year average P/B ratio of 3.84 , the current P/B ratio is approximately -14.51% higher. Relative to its 5-year average P/B ratio of 4.30, the current P/B ratio is about -23.62% higher. Celldex Therapeutics Inc (CLDX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -7.83%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.47% , the current FCF yield is about -100.00% lower.
3.29
P/B
Median3y
3.84
Median5y
4.30
-9.83
FCF Yield
Median3y
-7.83
Median5y
-6.47
Competitors Valuation Multiple
The average P/S ratio for CLDX's competitors is 6.32, providing a benchmark for relative valuation. Celldex Therapeutics Inc Corp (CLDX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CLDX increased by 17.13% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.32K to -12.46K.
The secondary factor is the Revenue Growth, contributed -100.00%to the performance.
Overall, the performance of CLDX in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Celldex Therapeutics Inc (CLDX) currently overvalued or undervalued?
What is Celldex Therapeutics Inc (CLDX) fair value?
How does CLDX's valuation metrics compare to the industry average?
What is the current P/B ratio for Celldex Therapeutics Inc (CLDX) as of Dec 05 2025?
What is the current FCF Yield for Celldex Therapeutics Inc (CLDX) as of Dec 05 2025?
What is the current Forward P/E ratio for Celldex Therapeutics Inc (CLDX) as of Dec 05 2025?